Penicillamine
Cuprimine, Depen (penicillamine) is a small molecule pharmaceutical. Penicillamine was first approved as Depen on 1982-01-01. It is used to treat biliary liver cirrhosis, cystinuria, hepatolenticular degeneration, lead poisoning, and mercury poisoning amongst others in the USA. It is known to target delta-type opioid receptor and solute carrier organic anion transporter family member 1C1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| musculoskeletal diseases | D009140 |
| digestive system diseases | D004066 |
| nervous system diseases | D009422 |
| urogenital diseases | D000091642 |
| hereditary congenital and neonatal diseases and abnormalities | D009358 |
| skin and connective tissue diseases | D017437 |
| nutritional and metabolic diseases | D009750 |
| immune system diseases | D007154 |
| signs and symptoms pathological conditions | D013568 |
| chemically-induced disorders | D064419 |
Trade Name
FDA
EMA
Cuprimine, Depen (generic drugs available since 2019-05-07)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cuprimine | New Drug Application | 2020-10-01 |
| penicillamine | ANDA | 2023-02-16 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatolenticular degeneration | D006527 | Orphanet_905 | E83.01 | 1 | — | 1 | — | — | 2 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | 1 | 1 | — | — | 1 |
| Lead poisoning | D007855 | T56.0 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system neoplasms | D016543 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PENICILLAMINE |
| INN | penicillamine |
| Description | D-penicillamine is an optically active form of penicillamine having D-configuration. Pharmaceutical form (L-form is toxic) of chelating agent used to treat heavy metal poisoning. It has a role as a chelator, an antirheumatic drug, a drug allergen and a copper chelator. It is a penicillamine and a non-proteinogenic alpha-amino acid. It is an enantiomer of a L-penicillamine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(S)[C@@H](N)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 52-67-5 |
| RxCUI | 7975 |
| ChEMBL ID | CHEMBL1430 |
| ChEBI ID | 7959 |
| PubChem CID | 5852 |
| DrugBank | DB00859 |
| UNII ID | GNN1DV99GX (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,773 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cuprimine, Penicillamine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
43 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more